Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Keymed Biosciences Inc (2162)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
35.60 -0.60    -1.66%
03/05 - Closed. Currency in HKD ( Disclaimer )
Type:  Equity
Market:  Hong Kong
ISIN:  KYG5252B1023 
  • Volume: 295,500
  • Bid/Ask: 35.15 / 35.75
  • Day's Range: 35.05 - 38.00
Keymed Biosciences 35.60 -0.60 -1.66%

Keymed Biosciences Inc Company Profile

 
Get an in-depth profile of Keymed Biosciences Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

613

Equity Type

ORD

Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin’s lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People’s Republic of China.

Contact Information

Address Building D2 No. 18 BioTown Middle Road
Tianfu International BioTown Shuangliu District Chengdu, 610219
China
Phone 86 28 8861 0620
Fax -

Top Executives

Name Age Since Title
Gang Xu 49 2018 Senior VP & Executive Director
Cheuk Kin Law 61 2021 Independent Non Executive Director
Xiao-Fan Wang 67 2021 Independent Non-Executive Director
Bo Chen 49 2018 Executive Chairman & CEO
Qi Chen 48 2018 Senior VP & Non Executive Director
Changyun Wang 58 2018 Senior VP & Executive Director
Yilun Liu 36 2021 Non Executive Director
Min Chuan Wang 44 2021 Non Executive Director
Yang Ke 67 2021 Independent Non Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

2162 Comments

Write your thoughts about Keymed Biosciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email